Krynica Vitamin S.A.

Krynica Vitamin S.A.

KVT.WA
Krynica Vitamin S.A.PL flagWarsaw Stock Exchange
13.15
PLN
-0.05
- -
161.09MMarket Cap
Krynica Vitamin S.A.
KVT.WA
(Warsaw Stock Exchange)

Recent

price

13.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.98
13.49
13.61
16.79
21.98
24.22
36.43
32.26
30.78
29.32
31.66
29.08
31.45
Revenue per Share
0.07
1.11
0.12
0.43
0.41
0.58
4.62
1.27
1.07
-0.55
1
0.98
1.17
Basic EPS, GAAP
0.05
-0.12
-0.23
0.2
-0.65
0.16
4.78
-0.6
-0.14
1.12
1.65
2.02
2.09
Free Cash Flow per Basic Share
0.03
- -
0.74
0.17
0.24
0.66
2.24
1.47
- -
0.2
- -
0.27
- -
Dividend per Share
0.14
2.61
1.52
1.65
1.57
1.88
4.12
0.56
2.57
0.95
2.5
2.48
2.57
Book Value per Share
0.22
4.9
4.09
4.37
4.54
4.26
6.38
6.13
7.23
6.51
7.41
8.06
7.48
Tangible Book Value per Share
170
12
12
12
12
12
12
12
12
12
12
12
12
Basic Weighted Avg Shares
167
165
167
206
269
297
446
395
377
359
388
356
385
Sales/Revenue/Turnover
10.83
10.25
3.81
3.64
3.17
3.88
17.56
5.92
5.54
2.4
4.57
5.86
4.98
Operating Margin (%)
3
4
6
8
8
9
11
13
14
15
14
15
14
Depreciation Expense
12
14
2
5
5
7
57
16
13
-7
12
12
14
Net Income, GAAP
24.08
20.18
7.05
20.83
16.22
14.49
20.53
25.81
7.55
- -
11.44
19.4
11.29
Effective Tax Rate (%)
7.23
8.2
0.9
2.55
1.88
2.38
12.68
3.94
3.47
-1.86
3.15
3.35
3.71
Profit Margin (%)
-2
10
-5
-5
-24
-31
-11
-19
-13
-22
-15
1
-20
Working Capital
11
7
17
14
17
33
28
32
29
23
17
14
9
LT Debt
39
61
51
54
56
55
81
78
91
82
94
103
95
Total Equity
- -
19.9
7.59
7.31
7.98
9.36
50.84
12.97
13.24
- -
11.49
12.28
12.64
Return on Invested Capital (%)
- -
30.47
4.47
12.07
10.46
11.27
66.93
20.76
19.16
- -
19.66
19.46
26.2
Return on Capital (%)
- -
48.03
5.95
27.1
25.6
33.42
154.1
54.35
68.28
-30.96
57.82
39.22
67.9
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
23
32
26
LT Borrowings
11
10
9
LT Finance Leases
- -
7
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
127
99
110

Working Capital

FRC

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
102
94
93
Cash, Cash Equivalents & STI
4
- -
- -
Accounts Receivable, Net
54
46
42
Inventories
41
40
44
Total Current Liabilities
117
109
113
Payables & Accruals
- -
- -
- -
ST Debt
23
32
26
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.6%
5.51%
9.18%
Free Cash Flow
125.22%
-199.71%
22.56%
Net Income, GAAP
37.28%
-104.99%
-2.29%
Sales/Revenue/Turnover
9.48%
-4.19%
-8.15%
Total Cash Common Dividend
- -
- -
35.02%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
82
107
113
86
388
2025
80
101
68
- -
356
2026
85
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
- -
0.54
- -
1
2025
0.08
0.41
- -
- -
0.98
2026
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.27
- -
- -
0.27
2026
- -
- -
- -
- -
- -
Business
Krynica Vitamin S.A. Krynica Vitamin S.A. is a Poland-based contract manufacturer specializing in fast-moving consumer goods (FMCG), primarily producing non-alcoholic and low-alcoholic beverages; energy drinks, functional and isotonic drinks, metabolism-boosting beverages, vitamin dietary supplements, flavored waters, multifruit drinks with pulp, carbonated soft drinks (CSDs), alcopops, ciders, malt beverages, coffee drinks, and dairy drinks for global brands, private labels, and supermarket chains. Founded nearly 30 years ago and headquartered at ul. Matyldy 35 in Warsaw, Poland, the company operates one of Europe's largest production facilities with five lines capable of filling cans, PET bottles, and glass bottles at a capacity exceeding 400 million units annually; it serves an international customer base across 38 countries on all continents, including the US, UK, Germany, Poland, Czech Republic, and Slovakia, through its own R&D laboratory for product development and formula creation, as well as co-packing for cosmetics and sport supplements. Recent developments include a statute change registered in October 2025, multiple director transactions and share dealings by insiders such as Zinat in early October 2025, release of the H1 2025 interim report in September 2025, and a prior new long-term contract with Schweppes International Limited positioning it as one of few global suppliers.